• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gold 2023: Highlights for primary care.

作者信息

Agustí Alvar, Sisó-Almirall Antoni, Roman Miguel, Vogelmeier Claus F

机构信息

Cátedra Salud Respiratoria, Univ. Barcelona, Hospital Clinic, IDIBAPS and CIBERES, Barcelona, Spain.

Consorci d'Atenció Primària de Salut Barcelona Esquerre (CAPSBE). Grup de Recerca Transversal en Atenció Primària (IDIBAPS). Departament de Medicina, Universitat de Barcelona, Barcelona, Spain.

出版信息

NPJ Prim Care Respir Med. 2023 Jul 31;33(1):28. doi: 10.1038/s41533-023-00349-4.

DOI:10.1038/s41533-023-00349-4
PMID:37524724
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10390461/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/a513c36574a9/41533_2023_349_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/3b55c8800be5/41533_2023_349_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/a567d6e6fddf/41533_2023_349_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/03c826fe7ad4/41533_2023_349_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/55ba446f5c44/41533_2023_349_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/a513c36574a9/41533_2023_349_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/3b55c8800be5/41533_2023_349_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/a567d6e6fddf/41533_2023_349_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/03c826fe7ad4/41533_2023_349_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/55ba446f5c44/41533_2023_349_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5236/10390461/a513c36574a9/41533_2023_349_Fig5_HTML.jpg

相似文献

1
Gold 2023: Highlights for primary care.《2023年黄金标准：基层医疗要点》
NPJ Prim Care Respir Med. 2023 Jul 31;33(1):28. doi: 10.1038/s41533-023-00349-4.
2
Multi-component assessment of chronic obstructive pulmonary disease: an evaluation of the ADO and DOSE indices and the global obstructive lung disease categories in international primary care data sets.多组分评估慢性阻塞性肺疾病：对 ADO 和 DOSE 指数以及国际初级保健数据集全球阻塞性肺病分类的评估。
NPJ Prim Care Respir Med. 2016 Apr 7;26:16010. doi: 10.1038/npjpcrm.2016.10.
3
Costs of pharmacotherapy of chronic obstructive pulmonary disease in relation to changing Global Initiative for Chronic Obstructive Lung Disease guidelines (2007, 2011, and 2017 updates).慢性阻塞性肺疾病药物治疗的成本与全球慢性阻塞性肺疾病倡议指南的变化有关（2007、2011 和 2017 年更新）。
Pol Arch Intern Med. 2019 May 31;129(5):308-315. doi: 10.20452/pamw.4487. Epub 2019 Mar 14.
4
[GOLD: some considerations on its application in our primary care].[《慢性阻塞性肺疾病全球倡议》：关于其在我们基层医疗中应用的一些思考]
Aten Primaria. 2004 Feb 15;33(2):108. doi: 10.1016/s0212-6567(04)79363-4.
5
A three-year follow-up of a nurse-led multidisciplinary pulmonary rehabilitation programme in primary health care: a quasi-experimental study.一项在初级卫生保健中由护士主导的多学科肺康复计划的三年随访：一项准实验研究。
J Clin Nurs. 2016 Apr;25(7-8):962-71. doi: 10.1111/jocn.13132. Epub 2016 Feb 16.
6
International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD).国际基层医疗呼吸组（IPCRG）指南：慢性阻塞性肺疾病（COPD）的管理
Prim Care Respir J. 2006 Feb;15(1):48-57. doi: 10.1016/j.pcrj.2005.11.003. Epub 2006 Jan 18.
7
Performance Measures in the Management of Chronic Obstructive Pulmonary Disease in Primary Care--A Retrospective Analysis.基层医疗中慢性阻塞性肺疾病管理的绩效指标——一项回顾性分析
Praxis (Bern 1994). 2015 Aug 19;104(17):897-907. doi: 10.1024/1661-8157/a002101.
8
Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease--2008 update--highlights for primary care.加拿大胸科学会慢性阻塞性肺疾病管理建议——2008年更新版——基层医疗要点
Can Respir J. 2008 May-Jun;15(4):219; author reply 219. doi: 10.1155/2008/851415.
9
Classification of patients with chronic obstructive pulmonary disease according to the Latin American Thoracic Association (ALAT) staging systems and the global initiative for chronic obstructive pulmonary disease (GOLD).根据拉丁美洲胸科学会（ALAT）分期系统和全球慢性阻塞性肺疾病倡议（GOLD）对慢性阻塞性肺疾病患者进行分类。
Arch Bronconeumol. 2017 Mar;53(3):98-106. doi: 10.1016/j.arbres.2016.08.015. Epub 2016 Dec 10.
10
GOLD in Practice: Chronic Obstructive Pulmonary Disease Treatment and Management in the Primary Care Setting.实践中的 GOLD：初级保健环境中的慢性阻塞性肺疾病治疗和管理。
Int J Chron Obstruct Pulmon Dis. 2021 Feb 12;16:289-299. doi: 10.2147/COPD.S222664. eCollection 2021.

引用本文的文献

1
Effects of the beach chair position on respiratory mechanics in patients with chronic obstructive pulmonary disease hospitalized in intensive care unit.沙滩椅位对入住重症监护病房的慢性阻塞性肺疾病患者呼吸力学的影响。
BMC Anesthesiol. 2025 Jul 21;25(1):355. doi: 10.1186/s12871-025-03199-4.
2
Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study.西班牙接受布地奈德/格隆溴铵/福莫特罗治疗慢性阻塞性肺疾病患者的特征：AURA研究
Int J Chron Obstruct Pulmon Dis. 2025 Apr 9;20:999-1008. doi: 10.2147/COPD.S490227. eCollection 2025.
3

本文引用的文献

1
Treatable Traits in Airway Disease: From Theory to Practice.气道疾病可治疗的特征：从理论到实践。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):713-723. doi: 10.1016/j.jaip.2023.01.011. Epub 2023 Feb 1.
2
Lifetime spirometry patterns of obstruction and restriction, and their risk factors and outcomes: a prospective cohort study.阻塞性和限制性通气功能障碍的终身变化模式及其危险因素和结局：一项前瞻性队列研究。
Lancet Respir Med. 2023 Mar;11(3):273-282. doi: 10.1016/S2213-2600(22)00364-2. Epub 2022 Oct 14.
3
Lifetime lung function trajectories and COPD: when the train derails.
Practical Guidelines by the Andalusian Group for Nutrition Reflection and Investigation (GARIN) on Nutritional Management of Patients with Chronic Obstructive Pulmonary Disease: A Review.
《安达卢西亚营养反思与研究小组（GARIN）关于慢性阻塞性肺疾病患者营养管理的实用指南：综述》。
Nutrients. 2024 Sep 14;16(18):3105. doi: 10.3390/nu16183105.
4
Treatment Adherence and Health Status of Patients With COPD Under Treatment With Salmeterol/Fluticasone via the Elpenhaler® Device: The AHEAD Study.采用 Elpenhaler®装置治疗沙美特罗/氟替卡松的 COPD 患者的治疗依从性和健康状况：AHEAD 研究。
Clin Respir J. 2024 Jul;18(7):e13803. doi: 10.1111/crj.13803.
5
Increasing exercise capacity and physical activity in the COPD patient.提高慢性阻塞性肺疾病患者的运动能力和身体活动水平。
Breathe (Sheff). 2024 Jun 11;20(2):230347. doi: 10.1183/20734735.0347-2023. eCollection 2024 Jun.
6
Exploring the novel duo of Reticulocalbin, and Sideroflexin as future biomarker candidates for Exacerbated Chronic Obstructive Pulmonary Disease.探索网织钙结合蛋白和铁转运蛋白这两种新型蛋白作为慢性阻塞性肺疾病急性加重期未来生物标志物候选物的可能性。
Clin Proteomics. 2024 Feb 14;21(1):10. doi: 10.1186/s12014-024-09459-8.
终身肺功能轨迹与慢性阻塞性肺疾病：当列车脱轨时。
Lancet Respir Med. 2023 Mar;11(3):221-222. doi: 10.1016/S2213-2600(22)00391-5. Epub 2022 Oct 14.
4
Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission.迈向消除慢性阻塞性肺疾病：柳叶刀委员会报告。
Lancet. 2022 Sep 17;400(10356):921-972. doi: 10.1016/S0140-6736(22)01273-9. Epub 2022 Sep 5.
5
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision.慢性阻塞性肺疾病的定义与命名：是时候修订了。
Am J Respir Crit Care Med. 2022 Dec 1;206(11):1317-1325. doi: 10.1164/rccm.202204-0671PP.
6
Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and COPD in COVID-19: A Systematic Literature Review and Meta-Analyses.2019冠状病毒病中哮喘和慢性阻塞性肺疾病的流行病学、医疗资源利用及死亡率：一项系统文献综述和荟萃分析
J Asthma Allergy. 2022 Jun 17;15:811-825. doi: 10.2147/JAA.S360985. eCollection 2022.
7
Chronic Bronchial Infection Is Associated with More Rapid Lung Function Decline in Chronic Obstructive Pulmonary Disease.慢性支气管感染与慢性阻塞性肺疾病肺功能下降速度加快有关。
Ann Am Thorac Soc. 2022 Nov;19(11):1842-1847. doi: 10.1513/AnnalsATS.202108-974OC.
8
Using a smartphone application maintains physical activity following pulmonary rehabilitation in patients with COPD: a randomised controlled trial.使用智能手机应用程序维持 COPD 患者肺康复后的体力活动：一项随机对照试验。
Thorax. 2023 May;78(5):442-450. doi: 10.1136/thoraxjnl-2021-218338. Epub 2022 Apr 21.
9
Genetics of chronic obstructive pulmonary disease: understanding the pathobiology and heterogeneity of a complex disorder.慢性阻塞性肺疾病的遗传学：理解复杂疾病的病理生物学和异质性。
Lancet Respir Med. 2022 May;10(5):485-496. doi: 10.1016/S2213-2600(21)00510-5. Epub 2022 Apr 12.
10
Pathogenesis of chronic obstructive pulmonary disease: understanding the contributions of gene-environment interactions across the lifespan.慢性阻塞性肺疾病的发病机制：了解基因-环境相互作用在整个生命周期中的贡献。
Lancet Respir Med. 2022 May;10(5):512-524. doi: 10.1016/S2213-2600(21)00555-5. Epub 2022 Apr 12.